Oncolytics Biotech is a biotechnology business based in the US. Oncolytics Biotech shares (ONCY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.26 – an increase of 1.61% over the previous week.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.26 |
|---|---|
| 52-week range | $0.84 - $1.80 |
| 50-day moving average | $0.99 |
| 200-day moving average | $1.07 |
| Wall St. target price | $4.81 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.28 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.35 from 2024-10-18
| 1 week (2024-10-15) | 8.87% |
|---|---|
| 1 month (2024-09-20) | 46.12% |
| 3 months (2024-07-22) | 32.35% |
| 6 months (2024-04-22) | 29.81% |
| 1 year (2023-10-20) | -12.90% |
|---|---|
| 2 years (2022-10-21) | 8.00% |
| 3 years (2021-10-18) | N/A |
| 5 years (2019-10-22) | 190.20% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -71.33% |
| Return on equity TTM | -138.22% |
| Profit margin | 0% |
| Book value | $0.24 |
| Market Capitalization | $103.3 million |
TTM: trailing 12 months
We're not expecting Oncolytics Biotech to pay a dividend over the next 12 months.
Oncolytics Biotech's shares were split on a 10:95 basis on 24 May 2018 . So if you had owned 95 shares the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Oncolytics Biotech shares – just the quantity. However, indirectly, the new 850% higher share price could have impacted the market appetite for Oncolytics Biotech shares which in turn could have impacted Oncolytics Biotech's share price.
Over the last 12 months, Oncolytics Biotech's shares have ranged in value from as little as $0.8401 up to $1.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncolytics Biotech's is 1.348. This would suggest that Oncolytics Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oncolytics Biotech Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.